SEC Tracker
Get the app

Mannatech MTEX

Mannatech FY 2024: revenue $117.9M, down 11%; diluted EPS $1.32

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Mannatech reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$117.9M−11% from $132.0M in FY 202310-K income statement, on EDGAR
  2. Net income$2.5MAgainst −$2.2M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS$1.32Against −$1.20 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$11.4M+47% from $7.7M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations$2.3MAgainst −$2.4M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Mannatech files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. LeonaBio ATHA public float $10M, Jun 30, 2025
  2. Traws Pharma ONTX public float $10M, Jun 30, 2025
  3. BioCardia BCDA public float $10M, Jun 30, 2025
  4. Alaunos Therapeutics TCRT public float $10M, Jun 30, 2025
  5. Scienture Holdings SCNX public float $10M, Jun 30, 2025